The use of TPLSM imaging to monitor the signals from biosensor proteins in living animals is of interest to many laboratories because it allows noninvasive detection of spatial and temporal characteristics of specific cell signaling or metabolic events. These genetically encoded biosensor proteins contain reporter modules that typically consist of FPs that are directly linked to sensing units that detect specific cellular events 1 . Many biosensor probes rely on FRET to report the changes in protein conformation that occur in response to the cellular event [1] [2] [3] [4] [5] [6] . There are, however, substantial challenges to the use of TPLSM to detect the FRET signals from biosensor probes in intact tissues; these issues fall into three general categories: (i) issues related to the 2PE characteristics of the biosensor probes; (ii) difficulties in expressing the genetically encoded biosensors in the desired cell type in living animals; and (iii) problems associated with conducting high-resolution microscopy in living animals. These three challenges are discussed further in the following sections, but this Protocol specifically addresses the first issue: identification, characterization and validation of a FRET-based FP biosensor suitable for TPLSM in intact tissues.
desired tissue in a particular mouse model to obtain unambiguous measurements of changing cell signaling events 12 .
Viral transduction is an alternative approach that offers rapid biosensor probe expression in living animals without the need for lengthy breeding strategies to achieve stable expression. However, the challenge for in vivo administration of viral vectors is to obtain expression of the biosensor probes in the relevant cell types. The expression of probes in a particular tissue can be achieved using cell type-specific promoters that restrict the biosensor expression to the target cells. However, if the cells of interest can be identified based on morphology, it might not be necessary to achieve selective expression in specific cell populations. Further, the systemic administration of unmodified adenovirus (Ad) generally results in the accumulation of the transgene in the liver and spleen 20 , and thus the tropism to these organs can be exploited for imaging studies.
High-resolution microscopy in living animals
Intact, living organisms present unique challenges for microscopy. First, the physiological welfare of the animal must be continuously monitored and maintained while the animal is on the microscope stage. Second, in most cases, the tissue of interest must be surgically exposed, requiring the development of methods for anesthesia and delicate surgery. Third, the tissue must be immobilized so that motion induced by respiration and the heartbeat is reduced to submicron levels.
The solutions to these challenges vary depending on the equipment used and the particular organ to be imaged. In our studies of kidney and liver [21] [22] [23] [24] , an inverted microscope stand is used to image the surgically exposed organs that are secured to a glassbottom dish (Fig. 1) . The anesthetized animal is placed on the microscope stage, and the animal's temperature is maintained using a heating pad and monitored using a rectal thermometer. Generally, tissue motion can be minimized by careful placement of the tissue, and can be reduced further by bonding small regions of the tissue to the coverglass with cyanoacrylate adhesive. In addition, gating the image collection to respiration can minimize the motion artifacts in tissues such as the lung 25, 26 . Finally, motion-induced distortions can be eliminated from the collected images using various methods of digital image analysis [27] [28] [29] [30] [31] .
Quantitative intravital microscopy is also complicated by the inevitable loss of signal that occurs when imaging highly scattering biological tissues. Therefore, the intensity measurements obtained from different depths cannot be directly compared. In this regard, using FRET-based biosensors can be advantageous. The ratio images obtained from biosensors will be minimally affected by depth, provided that the scattering and absorption do not vary substantially for the emission wavelengths of the probe. Although we find no evidence of an effect of depth on FRET measurements obtained in vivo, minor effects were observed in other studies 32 . Therefore, biosensor measurements collected over a large range of depths should be evaluated for systematic effects of depth on the FRET ratio. In general, the effects of depth on ratiometric measures can be minimized by using non-descanned detectors that are less susceptible to the effects of light scatter, and by avoiding FPs with widely different emission spectra.
Development of the protocol
Previously, we described the characterization of FPs for FRET biosensor probes specifically intended for intravital imaging using TPLSM 33 . As the cyan FPs (CFPs) are optimally excited at close to the power maximum of the Ti-sapphire lasers used in most TPLSM systems, we focused our evaluations of potential FRET donors on the newer variants of the CFPs that have improved brightness and photostability, and no photoswitching behavior [34] [35] [36] [37] . On the basis of previous studies demonstrating that wavelengths near 800 nm can be used for relatively selective excitation of CFP over yellow FP (YFP) 38, 39 , we focused our evaluations of potential FRET acceptors on newer, improved variants of YFP. On the basis of these studies, we identified monomeric (m)Turquoise 35 and mVenus 40 as optimal FPs for TPLSM. We found that illumination at 810 nm efficiently excited mTurquoise with minimal direct excitation of mVenus 33 . The selective excitation of mTurquoise at 810 nm allows ratiometric FRET measurements in vivo using TPLSM at a single excitation wavelength. Moreover, the use of the CFP and YFP is compatible with most TPLSM configurations.
A critical step in the acquisition of measurements from FRETbased biosensors is validation of the sensitivity of the method. It is necessary to demonstrate that measurements of subtle changes in the FRET ratio truly reflect the responses of the biosensor to cellular events. In general, FRET measurements should be reproduced using multiple methods. For example, FRET estimates based on measurements of sensitized emissions should be complemented with estimates from acceptor photobleaching or fluorescence lifetime measurements 33 . Given the inherent challenges of intravital microscopy, our goal was to develop a protocol that would minimize the validation studies that must be conducted. We accomplish this by providing a set of completely validated FRET standards and a simple method by which end users can characterize and optimize FRET measurements in their own systems.
Overview of the procedure
Here we describe a protocol in which a TPLSM system can be optimized and validated for FRET measurements in studies of cultured cells, before studies in living animals (Fig. 2) . We demonstrate intravital FRET biosensor imaging using an AKAR biosensor of PKA activity, expressed by adenoviral transduction of the mouse liver. Figure 1 | Schematic overview of the setup for measuring biosensor activity in a living animal. After viral transduction of a biosensor probe in mice, activity of the probe is monitored in the anesthetized animal. The procedure uses selective 2PE of mTurquoise at 810 nm to make ratiometric FRET measurements in vivo. To image probe activity in the liver, the left lateral lobe of the liver is carefully lifted and secured to a glass-bottom plate. The mouse is then placed ventral side down on a heated microscope stage and covered with a warming blanket, and the liver is imaged using a longworking-distance water-immersion objective. PMT, photomultiplier tube.
Our approach to intravital measurements of FRET biosensor activity involves four stages: (i) characterization of the emission spectra and the determination of spectral cross-talk correction factors for the donor and emission FPs in the user's system; (ii) validation of the experimental system for measuring FRET using FRET standards expressed in cells in culture; (iii) validation of the FRET biosensor for measurements from cells in culture; and (iv) measurement of FRET biosensor responses in cells in living animals.
Measurement of spectral cross-talk correction factors. The imaging protocol described here exploits the relatively selective 2PE of mTurquoise 35 over mVenus 40 using illumination at 810 nm, which enables the measurement of FRET ratios from single, twochannel images (Fig. 3) . However, the accurate measurement of FRET efficiencies (E FRET ) requires the application of correction factors for spectral cross talk (Box 1). These correction factors are entirely dependent on the configuration and performance of the microscope system, and must be measured for each system. Characterization and validation of FRET measurements using FRET standards. The FRET standards are critical tools for both verifying the biological model and optimizing the particular imaging system used for FRET measurements 41 . By providing a range of calibrated, reproducible E FRET values, the FRET standards allow the user to evaluate the performance of the system for the detection of FRET, and, importantly, allow an assessment of the sensitivity of the measurements (described in ANTICIPATED RESULTS). We have developed plasmids for a set of fully validated FRET standards, based on mTurquoise and mVenus (see Fig. 2 ; sequence information is provided in the Supplementary Data plasmids are available from the authors upon request). Measurements of E FRET obtained from living cells expressing these standards (using the approach described in Box 1) are used to validate and optimize the user's system for the detection of FRET in mTurquoise-mVenus-based biosensors.
Validation of FRET biosensor probe activity in cultured cells.
To verify and fully characterize the performance of the FRET biosensor in the user's system, preliminary studies are conducted in cultured cells; these can be manipulated to identify the full range Step 15
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Step 16; Box 1 -8 ) with a series of standards that are used to evaluate and optimize the TPLSM system, and to determine the SBT components when using 2PE at 810 nm (PROCEDURE Steps 9-16). Then, the FRET standards are used to evaluate the sensitivity of the system for the accurate measurement of E FRET (PROCEDURE Steps 17-21). The biosensor probe of interest is then verified in a cell model by measuring changes in the Venus to Turquoise ratio over time in response to suitable activators of the targeted signaling pathway (PROCEDURE Steps [22] [23] [24] [25] [26] [27] . Once the system and biosensor have been verified, studies in the living animal are conducted (PROCEDURE Steps 28-36). The relative 2PE spectral scans for (a) mTurquoise and (b) mVenus were acquired from living cells by measuring fluorescence emissions over a range of excitation wavelengths at a constant laser power and a detector scaling factor of 1; the red bar indicates excitation at 810 nm, used in this protocol. To provide fluorescence excitation spectra that were independent of variations at the output of the laser at different wavelengths, spectral variation in laser power was eliminated by adjusting the laser power to a constant value at each wavelength, as measured using a Thorlabs PM100D power meter with λ correction, mounted on the microscope stage 33 . The emission signals at the different excitation wavelengths were simultaneously detected in channel 1 (cyan, 454-494 nm) and channel 2 (yellow, 520-580 nm), and the images were acquired at each wavelength step, as described in the Experimental Design section. Image adapted with permission from ref. 33) , American Physiological Society.
of FRET ratios provided by the biosensor under physiological conditions. Here, an AKAR biosensor 6, 42 with a reporter module consisting of mTurquoise and circular permuted (cp)Venus FPs (AKAR4.1) 33 is used to monitor PKA activity in living cells. The response of the AKAR4.1 probe expressed in cells treated with a specific PKA agonist is used to characterize the performance of the system for measurements of changing FRET ratios.
Measurements of biosensor probe activity in the living animal.
Once the imaging system has been validated using the FRET standards, and the performance of the biosensor has been verified in living cells in culture, the final step is to apply the information collected in the in vitro studies to use the FRET probe to assay cellular function in a living animal. We use the expression of Ad AKAR4.1 in the mouse liver to demonstrate the use of this protocol to measure the activity of the PKA pathway in vivo.
Limitations of the approach
The protocol described here is designed for compatibility with the commonly available commercial TPLSM systems equipped with a single Ti-sapphire laser and detection pathways compatible with the emission spectra of CFP and YFP. We recognize that investigators may conduct their TPLSM studies on a shared instrument for which the non-descanned detectors may not be configured for the
Box 1 | Digital analysis of SBT for the determination of FRET efficiency • tIMInG ~ 1 h
The optical pathway of the microscope system must be optimized for the detection of the mTurquoise-mVenus-based biosensor probe when excited at 810 nm. This is achieved by imaging cells that express either mTurquoise or mVenus alone (PROCEDURE . Spectral scanning on systems with spectral detectors, or careful selection of emission filters on filter-based systems, will allow the user to adjust the optimal bandwidth for detection of the donor and acceptor signals (PROCEDURE Step 11). Once the donor and acceptor emission bandwidths are set, it is then necessary to measure the contributions of SBT to the signals detected in the FRET channel (excitation 810 nm, acceptor emission). The subtraction of the SBT signals from the signal that is detected in the FRET channel (FRET raw ) provides the corrected FRET (FRET corr ) signal 51 Measurements from cells expressing only mVenus are obtained using both 810-nm and 960-nm excitation to determine the fraction of the acceptor signal that arises from the direct excitation of mVenus at 810 nm. For our system, we determined that the ASBT fraction was 0.030. Because this protocol uses a single excitation wavelength (810 nm) to measure FRET standard and biosensor activity, it is also necessary to approximate the intensity in the acceptor channel (Ch2-960) from the measurement at 810 nm (i.e., the fractional excitation of mVenus at 810 nm). This is accomplished by measuring the average I Ch2-810 /I Ch2-960 ratio from cells expressing a mixture of mTurquoise and mVenus, and cells expressing the low-FRET standard (Turquoise-TRAF-Venus). For our system, the average ratio was 0.344. Therefore, multiplication of the acceptor intensity measured with excitation at 810 nm by 2.91 (1/0.344) provides an approximation of the intensity in the acceptor channel, to allow correction for ASBT. For our microscope system, correction factor A is 2.91 × 0.03 = 0.087.
correction for donor sBt (DsBt).
Correction factor B (equation 1) is used to remove DSBT, the signal detected in the acceptor channel that results from donor emission bleed-through, and is determined from cells expressing only mTurquoise. Measurements from the donor-alone cells excited at 810 nm allowed us to determine that the donor bleed-through fraction was 0.295 on our system. Thus, the FRET corr can be determined as follows:
Determining Fret efficiency (E Fret ) for the Fret standards. The validation of the imaging system is accomplished by measurement of the FRET standards. Here, measurements are acquired from cells expressing a low E FRET standard (mTurquoise-TRAF-mVenus), and two high E FRET standards (mTurquoise-5AA-Venus and mTurquoise-10AA-Venus), as described in ANTICIPATED RESULTS. The low E FRET standard provides an indication of the threshold of detection, whereas the measurements from the two different high E FRET standards allow the user to assess the sensitivity of the system. The E FRET value is calculated as previously described 33,51,52 using the following equation: QY d and QY a denote the quantum yields of the donor and acceptor, respectively, where the quantum yield ratio for mTurquoise and mVenus is 1.474 (refs. 35,40) . S d and S a denote the spectral sensitivities of the donor and acceptor channels, respectively. The S d /S a ratio is approximated by the bandwidth ratio of channel 1 and channel 2. G d and G a are the detector gains for the donor and acceptor emission channels, respectively, and were set to a scaling factor of 1 for all measurements.
(1) (1)
efficient collection of cyan and yellow fluorescence. In this situation, it may be necessary to use the descanned detectors, which are typically easier to configure. As descanned detectors are located far from the back aperture of the objective, they collect less of the fluorescence scattered in the tissue, and thus provide poorer reach into biological tissues than non-descanned detectors located adjacent to the back aperture of the objective. The ideal design for a system dedicated to 2PE FRET studies would be one in which the non-descanned pathway were fitted with filters optimized for sensitive and specific detection of mTurquoise and mVenus. In addition, the objective lenses used to obtain subcellular resolution provide a field of view that is typically less than a millimeter across. Therefore, it can be difficult to draw general conclusions about cellular function based on observations collected within such a tiny window. More importantly, the microscope samples only the most superficial layers of biological tissues. Even TPLSM, which allows deeper imaging than confocal microscopy, is generally limited to depths of < 100 µm into tissue. Thus, TPLSM is incapable of analyzing populations of cells located deep in organs (e.g., renal medulla) or evaluating physiological properties below the surface of tumors.
Finally, the intravital setting presents substantial challenges to the expression of fluorescent biosensor probes. Here, we use Ad transduction to achieve high-level expression of a biosensor probe in the liver of mice. The Ad provides robust, but transient, expression of the transgenes. Further, there are typically inflammatory responses to the virus that can limit its use in prolonged studies. These problems are largely overcome by adeno-associated virus (AAV) or lentivirus vectors, which can achieve persistent transgene expression with minimal inflammatory responses. Importantly, there are many serotypes of AAVs that differ in their capsid protein structures, and this enables distinct tissue tropism for the different serotypes 20, 43 .
Advantages
A crucial component of this protocol is the use of the wellcharacterized FRET standards as a tool to validate that both the experimental model and the microscope system are optimized for sensitive measurements of FRET (ANTICIPATED RESULTS). Therefore, it is necessary that the end users determine the corrected FRET efficiency for each of the standards to assess the performance of their system and to compare their results with those obtained here (or from other studies, if different standards are used). The measurement of the FRET standards on the microscope system enables confirmation of the ratiometric FRET measurements acquired in vivo using the single-wavelength 2PE of the biosensor probes. The acquisition of single, twochannel images with TPLSM simplifies image collection, maximizing temporal resolution and minimizing the number of in vivo studies. The use of a single wavelength for 2PE offers additional advantages for the measurement of biosensor probe activity in intact tissue, avoiding delay in the collection of ratio images and the effects of shifts in laser alignment at different wavelengths.
Several groups have described the use of fluorescence lifetime imaging as an effective approach for measuring FRET in vivo [44] [45] [46] . The ratiometric approach offers a few key advantages over fluorescence lifetime-based approaches. First, it is easily implemented in most TPLSM systems, requiring no additional instrumentation. Second, the ratiometric approach provides better temporal resolution; whereas fluorescence-lifetime measurements typically require image collection over tens of seconds, images for ratiometric measurements can be collected in less than a second.
We demonstrate the use of our approach to measure PKA activity in vivo. However, we emphasize that this approach should be generalizable to other FRET-based biosensors, once the reporter module is modified to include mTurquoise and a suitable acceptor. For example, we have found very similar results using the optimized calcium biosensor probe Twitch2b (ref. 47 ). Thus, with minimal effort, the approach described here can be applied to many other biosensor probes by exchanging the earlier, more photolabile, variants of the CFPs. 19 and must be handled at biosafety level 2. The cell lines used in your research should be regularly checked to ensure that they are authentic and that they are not infected with mycoplasma. FP constructs (see Table 1 ). All FP constructs described here are available through the National Institutes of Health O'Brien Center for Advanced Renal Microscopic Analysis at the Indiana University School of Medicine. The plasmid sequences can be found in the Supplementary Data EQUIPMENT SETUP Intravital microscope system In our laboratory, intravital microscopy (IVM) is conducted as previously described 24 using a modified Olympus FV1000 spectral laser-scanning confocal microscope system, mounted on an Olympus IX81 stand, and modified for 2PE. Near-IR illumination, provided by a MaiTai HP Ti-sapphire laser (Spectra-Physics), is attenuated using a Pockels cell electro-optical attenuator (Conoptics), and the beam is expanded via a Keplerian collimator/beam expander. Images are acquired using an Olympus ×25, numerical aperture 1.05 XLPlan water-immersion objective (Fig. 1) . Fluorescence is collected using the Olympus FV1000 photomultiplier detectors on the descanned detection pathway. A FV1000 spectral detection system (spectral grating) is used to collect spectral data and to select emission wavelengths optimized for each FP. Laser power at the specimen plane is measured using a PM100D power meter (Thorlabs). 5| Add 9 µl of X-tremeGENE HP DNA Transfection Reagent to the diluted DNA (3:1 ratio of reagent to DNA). Pipette gently to mix.
MaterIals

6|
Incubate the mixture for 15-30 min at room temperature.
7|
Add 75 µl of the appropriate transfection complex to the cells in a drop-wise manner.
8|
Gently shake the chambered coverglass to ensure even distribution, and then incubate the cells at 37 °C in 5% (vol/vol) CO 2 for 24-48 h before imaging.
system evaluation and optimization-determination of the spectral ranges for the detectors • tIMInG 1.5-2 h 9| Prepare the TPLSM system. At least 30 min before image acquisition, turn on the system according to the manufacturer instructions, to ensure that power and alignment are completely stabilized before image collection. Tune and align the laser at 810 nm.  crItIcal step Allow the laser to warm and stabilize for ~30 min before imaging to ensure that the system is consistent for image collection.
10| Prepare to collect images for measurement of SBT. 24-48 h after transfection of cells with mTurquoise or mVenus (at Step 4), transfer transfected cells (from
Step 8) into a medium suitable for maintaining physiological pH in air, or into a chamber capable of maintaining a 5% (vol/vol) CO 2 environment. Mount the cells in a stage incubator set to maintain the cells at 37 °C.
11|
Optimize the microscope settings for optimal detection of mTurquoise and mVenus emissions. Users with filter-based systems should follow option A to verify that the correct filters and mirrors are in use. Users with spectral fluorescence detectors should follow option B to determine the spectral-range settings for the imaging system.  crItIcal step The SBT components that contaminate the FRET signal result from the donor (mTurquoise) emission that bleeds into the acceptor detection channel (donor SBT (DSBT)), and the direct excitation of the acceptor (mVenus) at the donor excitation wavelength (acceptor SBT (ASBT)). It is necessary to correct for SBT in order to accurately determine FRET efficiency. The SBT corrections are specific to each microscope system, and they are entirely dependent on spectral or filter settings on the microscope; thus, it is critical to always verify these settings on multiuser microscope systems.
(a) Verification of the setup of filter-based systems (i) Select the correct emission filters for the cyan and yellow channels, and the appropriate dichroic mirror.
(ii) Measure the signal from the cells expressing mTurquoise only and that from cells expressing mVenus only (from Step 8) to verify that the correct emission filters and dichroic mirrors are being used. (B) optimization of systems with spectral fluorescence detectors (i) Using cultured cells expressing mTurquoise only and cells expressing mVenus only (from Step 8), set the illumination to 810 nm, adjust illumination levels to fill the dynamic range of the detectors without saturation, and collect emission scans from ~420-600 nm. (ii) Evaluate the emission spectra of mTurquoise and mVenus, and identify the optimal wavelength ranges for selectively detecting mTurquoise and mVenus fluorescence emissions. For our system, these ranges were determined to be 454-494 for detection of mTurquoise and 520-580 for detection of mVenus (Fig. 1) . ? trouBlesHootInG system evaluation and optimization-sBt and fractional excitation • tIMInG 4 h  crItIcal This protocol uses a single excitation wavelength (810 nm) to measure FRET standard and biosensor activity. The FRET standards are used for system validation, so it is necessary to determine the corrected E FRET for each standard excited at this wavelength (Step 21). This requires the measurement and removal of the DSBT and ASBT (Steps 13 and 16, and Box 1). As a single excitation wavelength is used, the determination of the ASBT also requires the estimation of the fractional excitation of Venus at 810 nm. This is accomplished by measuring the average I Ch2-810 /I Ch2-960 ratio from cells expressing a mixture of mTurquoise and mVenus (mTurquoise + mVenus), as well as measuring the low-FRET standard (Turquoise-TRAF-Venus, Step 16). 
15| Collect images for measurement of fractional excitation of mVenus at 810 nm.
Using the same wavelengths, collect images of living cells expressing both mTurquoise and mVenus under conditions of minimal FRET (e.g., a mixture of the two, or a low-FRET standard, from Step 8), first with illumination at 810 nm and then again using illumination at 960 nm.
Laser power at 960 nm should be adjusted to be equivalent to that used at 810 nm, as measured with a laser power meter at the specimen plane.  crItIcal step Tuning a Ti-sapphire laser to different wavelengths may lead to differences in laser alignment that can affect quantitative measures. It is critical to ensure that laser alignment is unaffected, or corrected, when changing between 810 and 960 nm. 
18|
Prepare the TPLSM system for imaging, as described in Step 9.
19|
Transfer transfected cells to a medium suitable for maintaining physiological pH in air, or to a chamber capable of maintaining a 5% (vol/vol) CO 2 environment. Mount the cells in a stage incubator set to maintain the cells at 37 °C.
20|
Using the same laser power and emission wavelength settings used in Steps 12 and 15, collect two-channel images of cells expressing each of the FRET standard constructs and cells coexpressing mTurquoise and mVenus (Step 4).  crItIcal step Transient co-transfection of cells with a mixture of the mTurquoise and mVenus plasmids will produce highly variable relative expression levels of the two different FPs. For this protocol, it is important to preselect cells for imaging that have intensity levels in both channels that are similar to the low-FRET efficiency standard (mTurquoise-TRAF-mVenus, which has a fixed 1:1 ratio of the donor and acceptor, with little donor quenching).
21|
Image analysis for measurements of FRET standards. Using image-processing software, identify regions of interest in several cells expressing FPs, and for each region measure the signal levels in the CFP and YFP channels. Correct these measurements for background by subtracting measurements obtained from nearby regions lacking fluorescence. For each cell, measure the FRET ratio and calculate E FRET (Box 1).  crItIcal step The 2PE method described here should readily distinguish the three FRET standards with the different linker lengths from one another based on the measured E FRET (see ANTICIPATED RESULTS). It is critical to use this approach to demonstrate that the TPLSM system is properly set up to obtain accurate measurements of E FRET and is capable of highsensitivity measurements from the biosensor probes in living cells. 
23|
24|
25|
Using the laser power and emission wavelength settings used in Steps 12, 15 and 17, collect a series of two-channel images of a field of cells expressing AKAR4.1 to establish baseline measurements.
26| Collect a series of images before and after activating the biosensor probe. Here, images were collected at 30-s intervals before and after the addition of Fsk to the culture medium (final concentration of 24 µM). Fsk-mediated activation of PKA is expected to induce a rapid and significant increase in the Venus to Turquoise emission ratio (ANTICIPATED RESULTS).
? trouBlesHootInG
27|
Image analysis for measurements of FRET biosensor responses. Using image-processing software, identify regions of interest in several cells expressing AKAR4.1, and for each region measure the signal levels in the CFP and YFP channels. Correct these measurements for background by subtracting measurements obtained from nearby regions lacking fluorescence.
For each cell at each time point, measure the normalized Venus to Turquoise emission ratio.  crItIcal step It is important to verify the function of the FRET-based biosensor probes using other methods, such as fluorescence-lifetime imaging microscopy or acceptor photobleaching measurements. In addition, it is important to demonstrate that the biosensor is reporting the correct cellular activity. Treatment of cells with unrelated signaling molecules or antagonists to the specific cellular pathway should not elicit the biosensor response. Moreover, point mutations in the bioactive linker (phosphorylation or binding sites) should abolish the changes in the probe response.
? trouBlesHootInG Measurement of the biosensor probe Fret response in the organ of a living animal-intravital microscopy • tIMInG 9 h  crItIcal Once the biosensor has been validated, the 2PE ratiometric method can be used to measure biosensor probe activity in the targeted organ in a living animal. Here, we demonstrate the approach by measuring the effect of glucagon on PKA activity in cells in the intact mouse liver in mice transduced with the Ad AKAR4.1 vector. 28| Transduction of mice with a FRET biosensor. 7 d before imaging, introduce 0.2 ml of the Ad AKAR4.1 vector (4.8 × 10 10 particles) into mice by tail-vein injection, using standard methods (e.g., http://www.procedureswithcare.org. uk/intravenous-injection-in-the-mouse/). ! cautIon All animal studies must be approved by the relevant institutional animal care and use committee and must conform to the applicable national regulations. Studies of animals transduced with Ad must be conducted in compliance with institutional biosafety standards.
29| Image collection of FRET biosensor responses in the liver of a living mouse.
Physiological manipulations and animal preparations will vary according to the study. To prepare for activation of PKA in liver via glucagon 49 , withdraw food from mice 3 h before scheduled imaging. ? trouBlesHootInG 30| Prepare the TPLSM system for imaging, as described in Step 9.
31|
Externalize the left lateral lobe of the liver and prepare for IVM imaging through a glass-bottom plate using previously described methods 24 .
32| Place the animal on the warmed microscope stage, identify a field of hepatocytes expressing AKAR4.1 and, using the same microscope settings used in Steps 12, 15, 17 and 26, collect a series of 3D image volumes (10 planes spanning 10 µm) in CFP and YFP channels to establish the baseline ratio. 3D stacks are collected to ensure sequential capture of hepatocyte cytosols despite residual vertical motion of the liver because of respiration.
33|
Continue to collect 3D image volumes during and following IP injection of glucagon (200 µg/kg) to monitor the increase in the FRET ratio resulting from activation in PKA. little energy transfer detected in cells that express a mixture of the unlinked mTurquoise and mVenus. The low-FRET-efficiency standard, mTurquoise-TRAFmVenus, should also have a low, but measurable, E FRET value (~5%) 33, 41, 50 . By contrast, measurements from the cells expressing the highest E FRET standard, mTurquoise-5AA-Venus, produce E FRET values of ~45%. Critically, measurements from cells expressing the mTurquoise-10AA-Venus standard are expected to be ~36%, and should be readily distinguishable from the FRET standard with the shorter linker (Fig. 4) . These FRET standards allow the validation of the imaging system, and provide a clear indication of the sensitivity of the measurements. The FRET standards also provide a control for identifying changes in performance of the laser, optics or detectors that may compromise measurements under physiological conditions.
34|
2pe measurements of Fret-based biosensor probe activities in cultured cells
Biosensor validation is accomplished in studies in cultured cells expressing the biosensor that are treated with established methods to activate the cell-signaling event. For our studies, we transfected HEK293 cells with AKAR4.1 and monitored emissions in the cyan (454-494 nm) and yellow (520-580 nm) channels under illumination at 810 nm (Steps 22-27). After collecting a series of baseline images, the PKA agonist Fsk was added to a final concentration of 24 µM. As expected, Fsk induced a rapid and pronounced (1.4-fold) increase in the emission ratio of Ven/Turq (Fig. 5). 
2pe measurements of Fret-based biosensor probe activities in living animals
After validation of the microscope system and the biosensor, studies are next conducted in living animals. For our studies, we took advantage of the robust tropism of Ad for the mouse liver following tail-vein injection 20 ( Step 28). 7 d after injection with Ad AKAR4.1, the mice were fasted for 3 h, prepared for IVM, and then imaged as described above (Steps 29-33). Baseline images were collected, and imaging was continued after i.p. injection of glucagon (200 µg/kg), a treatment that has been previously shown to rapidly stimulate both cAMP and PKA in hepatocytes of fasted mice 49 . Similar to the results obtained with HEK-293 cells treated with Fsk, glucagon treatment in the living mouse induced a rapid 1.4-fold change in the emission ratio of Ven/Turq (Fig. 6) , indicating a rapid and sustained activation of PKA. A certain degree of cell-cell variability can be expected from cells in vivo; our earlier measurements 33 of 32 hepatocytes from three separate studies ranged from 1.14 to 1.827. 
